Rani Therapeutics Holdings, Inc. (RANI)

NASDAQ: RANI · IEX Real-Time Price · USD
3.420
-0.030 (-0.87%)
At close: Feb 27, 2024, 4:00 PM
3.392
-0.028 (-0.82%)
After-hours: Feb 27, 2024, 5:26 PM EST
-0.87%
Market Cap 177.13M
Revenue (ttm) n/a
Net Income (ttm) -35.66M
Shares Out 51.34M
EPS (ttm) -1.41
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 65,398
Open 3.500
Previous Close 3.450
Day's Range 3.370 - 3.500
52-Week Range 1.820 - 6.890
Beta 0.95
Analysts Strong Buy
Price Target 13.67 (+299.71%)
Earnings Date Mar 20, 2024

About RANI

Rani Therapeutics Holdings, Inc. operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a drug-agnostic oral delivery platform to deliver a variety of drug substances, including large molecules, such as peptides, proteins, and antibodies. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-102, a parathyroid hormone that is in Phase I clinical trial for th... [Read more]

Industry Biotechnology
Sector Healthcare
IPO Date Jul 30, 2021
Employees 163
Stock Exchange NASDAQ
Ticker Symbol RANI
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 3 analysts, the average rating for RANI stock is "Strong Buy." The 12-month stock price forecast is $13.67, which is an increase of 299.71% from the latest price.

Price Target
$13.67
(299.71% upside)
Analyst Consensus: Strong Buy
Stock Forecasts

News

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Rani Therapeutics Holdings, Inc. (NASDAQ: RANI)

NEW YORK , Jan. 9, 2024 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Rani Therapeutics Holdings, Inc. (NASDAQ: RANI) on behalf of the company's shareholders.  The investi...

7 weeks ago - PRNewsWire

Rani Therapeutics Announces Preclinical Pharmacodynamic Data on Transenteric Delivery of GLP-1 Incretin Triagonist

- Transenteric delivery of incretin triagonist of GLP-1, GIP, glucagon receptors elicits rapid weight loss in animal study –

2 months ago - GlobeNewsWire

Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update

- Cash runway extended into 2025 - - Announced strategic program prioritization, expansion of manufacturing and plans to streamline business operations - - Initiated Phase 1 clinical trial of RT-111, ...

3 months ago - GlobeNewsWire

Rani Therapeutics Announces Successful Oral Delivery of Monoclonal Antibody via High-Capacity Pill in Preclinical Study

- RaniPill ® HC achieved 4/4 successful drug delivery of orally administered Humira® (adalimumab) -

4 months ago - GlobeNewsWire

Rani Therapeutics to Present Abstract on RT-102 at the 2023 Annual Meeting of the American Society for Bone and Mineral Research

SAN JOSE, Calif., Oct. 12, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delive...

4 months ago - GlobeNewsWire

Rani Therapeutics Initiates Phase 1 Study of RT-111 (RaniPill® Containing Ustekinumab Biosimilar, CT-P43)

- Topline results from this study are expected in early Q1 2024 - Celltrion has a right of first negotiation for RT-111 following positive Phase 1 results SAN JOSE, Calif., Sept. 18, 2023 (GLOBE NEWSW...

5 months ago - GlobeNewsWire

Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies

- Two preclinical studies of RaniPill® HC achieved 18/20 successful drug delivery of orally administered teriparatide resulting in a cumulative 90% success rate

6 months ago - GlobeNewsWire

Rani Therapeutics to Participate in September Investor Conferences

SAN JOSE, Calif., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral deliv...

6 months ago - GlobeNewsWire

Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update

- Expansion of partnership with Celltrion for development of RT-105 to complement existing partnership for RT-111 - Appointment of Kate McKinley as Chief Business Officer - Presentation of three abstr...

7 months ago - GlobeNewsWire

Rani Therapeutics to Participate in August Investor Conferences

SAN JOSE, Calif., Aug. 04, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delive...

7 months ago - GlobeNewsWire

Rani Therapeutics' Presentation On Oral Delivery of PTH for Osteoporosis Named Presidential Poster Competition Winner at ENDO 2023 Annual Conference

SAN JOSE, Calif., June 21, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delive...

8 months ago - GlobeNewsWire

Rani Therapeutics Announces Acceptance of Late-Breaking Abstract of Oral Delivery of GLP-1 Agonist at the American Diabetes Association Annual Conference

SAN JOSE, Calif., June 08, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delive...

9 months ago - GlobeNewsWire

Rani Therapeutics and Celltrion Expand Partnership to Include Adalimumab Biosimilar for RT-105

This is the second deal announced between Rani and Celltrion, building upon a previously announced partnership for ustekinumab biosimilar for RT-111 This is the second deal announced between Rani and ...

9 months ago - GlobeNewsWire

Rani Therapeutics to Present at the Jefferies Healthcare Conference

SAN JOSE, Calif., June 01, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral delive...

9 months ago - GlobeNewsWire

Rani Therapeutics Announces Acceptance of Three Abstracts for Presentation at ENDO 2023 Annual Conference

SAN JOSE, Calif., May 31, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral deliver...

9 months ago - GlobeNewsWire

Rani Therapeutics Appoints Kate McKinley as Chief Business Officer

SAN JOSE, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral deliver...

9 months ago - GlobeNewsWire

Rani Therapeutics Reports First Quarter 2023 Financial Results; Provides Corporate Update

- Announced partnership with Celltrion on development of RT-111, a RaniPill GO capsule containing a biosimilar for the monoclonal antibody ustekinumab -

10 months ago - GlobeNewsWire

Rani Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

SAN JOSE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on the oral deliv...

11 months ago - GlobeNewsWire

Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update

- Anticipates initiating first Phase 2 clinical study in RT-102 in 2H of 2023 -

1 year ago - GlobeNewsWire

Rani Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results and Business Updates

Management to host conference call on Wednesday, March 22 at 4:30 p.m. ET Management to host conference call on Wednesday, March 22 at 4:30 p.m. ET

1 year ago - GlobeNewsWire

Celltrion and Rani Therapeutics Partner on Development of Oral Monoclonal Antibody Treatment

Celltrion will be Rani's exclusive supplier of ustekinumab biosimilar, CT-P43, for oral RT-111 RaniPill™ program Celltrion will be Rani's exclusive supplier of ustekinumab biosimilar, CT-P43, for oral...

1 year ago - GlobeNewsWire

Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update

- Preliminary feedback from FDA on RT-102 development plans; 505(b)(2) pathway for RT-102 could be suitable -

1 year ago - GlobeNewsWire

Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study

- RT-102 achieved all of its endpoints in the repeat-dose Part 2 of the Phase 1 Study -

1 year ago - GlobeNewsWire

Rani Therapeutics to Present at the Stifel Healthcare Conference

SAN JOSE, Calif., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical stage biotherapeutics company focused on the oral delive...

1 year ago - GlobeNewsWire

Rani Therapeutics Announces New RT-111 Development Program and Provides Corporate Update

- Rani announces preclinical development of RT-111, a RaniPill GO capsule containing ustekinumab biosimilar for the potential treatment of psoriatic arthritis, ulcerative colitis, Crohn's disease and ...

1 year ago - GlobeNewsWire